Azafaros Publishes Phase 2 Study Results for Nizubaglustat in Rare Genetic Disorders
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal
Image: Businesswire
Azafaros has published data from its Phase 2 RAINBOW study in the journal Molecular Genetics and Metabolism, showing that nizubaglustat effectively reduced disease progression and seizure burden in patients with GM2 gangliosidosis and Niemann-Pick type C disease. The results support ongoing Phase 3 trials.
- 01The Phase 2 RAINBOW study demonstrated that nizubaglustat was safe and well tolerated.
- 02Results indicated a reduction in disease progression and seizure burden for treated patients.
- 03Nizubaglustat has received multiple designations from regulatory agencies, including Rare Pediatric Disease Designation from the FDA.
- 04The study was randomized, double-blind, and placebo-controlled, focusing on safety and pharmacological profile.
- 05Azafaros aims to develop therapeutics for lysosomal storage disorders, addressing significant unmet medical needs.
Advertisement
In-Article Ad
Azafaros has announced the publication of data from its Phase 2 RAINBOW study of nizubaglustat in the peer-reviewed journal Molecular Genetics and Metabolism. The study focused on patients with genetically confirmed GM2 gangliosidosis and Niemann-Pick type C disease. Key findings include that nizubaglustat was safe and well tolerated, with encouraging signs of efficacy, particularly in reducing disease progression and seizure burden. CEO Stefano Portolano emphasized the importance of these results for the lysosomal disease community, reinforcing confidence in ongoing Phase 3 studies for GM1/GM2 gangliosidoses and NPC. The RAINBOW study was designed to evaluate the drug's safety, tolerability, and pharmacological profile, with topline results announced in 2024. Nizubaglustat is recognized for its potential in treating rare lysosomal storage disorders, having received multiple designations from regulatory bodies, including the FDA and EMA. Azafaros, founded in 2018, is committed to developing disease-modifying treatments for patients with rare genetic disorders.
Advertisement
In-Article Ad
The publication of the RAINBOW study data could lead to new treatment options for patients suffering from GM2 gangliosidosis and Niemann-Pick type C disease, addressing a significant unmet medical need.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of nizubaglustat as a treatment for rare diseases?
Connecting to poll...
Read the original article
Visit the source for the complete story.